The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: Possible genetic and cell-signaling mechanisms

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 431-445

  Quốc Luong, Khanh Vinh ^a   Nguyên, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Neoplasm; Non genomic factor; adrenergic antagonism; adrenergic blocker

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CELIPROLOL; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMCITABINE; HLA DR ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; NEBIVOLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE SYNTHASE; PROPRANOLOL; PROSTAGLANDIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUNITINIB; VASCULOTROPIN;

ACUTE LEUKEMIA; ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CARCINOMA; DPB1 GENE; DQA1 GENE; DQB1 GENE; DR1 GENE; DRB1 GENE; EWING SARCOMA; GENETIC VARIABILITY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HLA CLASS 2 GENE; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG CANCER; METASTASIS; MOLECULAR PATHOLOGY; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STOMACH CANCER; THYROID CARCINOMA; TUMOR GENE; UTERINE CERVIX CANCER;

EID: 84871627956     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S39153     Document Type: Review

References (265)

1. Badino GR, Novelli A, Girardi C, di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996;33(4-5):255-260.
2. Schuller HM, Cole B. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis. 1989;10(9):1753-1755.
3. Park PG, Merryman J, Orloff M, Schuller HM. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res. 1995;55(16):3504-3508.
4. Shang ZJ, Liu K, Liang de F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med. 2009;38(4): 371-376.
5. Kassahun WT, Guenl B, Ungemach FR, Jonas S, Abraham G. Expression and functional coupling of liver β2-adrenoceptors in the human hepatocellular carcinoma. Pharmacology. 2012;89(5-6):313-320.
6. Lin X, Luo K, Lv Z, Huang J. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. Hepatogastroenterology. 2012;59(114):584-588.
7. Zhao L, Yang F, Xu K, et al. Common genetic variants of the β2-adrenergic receptor affect its translational efficiency and are associated with human longevity. Aging Cell. 2012;11(6):1094-1101.
8. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201-1206.
9. Lamkin DM, Sloan EK, Patel AJ, et al. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav Immun. 2012;26(4):635-641.
10. Schuller HM, Al-Wadei HA, Ullah MF, Plummer HK 3rd. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis. 2012;33(1):191-196.
11. Al-Wadei HA, Plummer HK 3rd, Ullah MF, Unger B, Brody JR, Schuller HM. Social stress promotes and γ-aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. Cancer Prev Res (Phila). 2012;5(2):189-196.
12. Liu X, Wu WK, Yu L, et al. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem. 2008;105(1):53-60.
13. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118(11): 2744-2749.
14. Al-Wadei HA, Al-Wadei MH, Schuller HM. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One. 2012;7(1):e29915.
15. Hyltander A, Daneryd P, Sandström R, Körner U, Lundholm K. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer. 2000;36(3):330-334.
16. Gambardella A, Tortoriello R, Pesce L, Tagliamonte MR, Paolisso G, Varricchio M. Intralipid infusion combined with propranolol administration has favorable metabolic effects in elderly malnourished cancer patients. Metabolism. 1999;48(3):291-297.
17. Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. Epub July 20, 2012.
18. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol. 2012;127(2):375-378.
19. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011;171(8):779-781.
20. Toll L, Jimenez L, Waleh N, et al. {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther. 2011;336(2):524-532.
21. Long H, et al. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol. 2010;5:98.
22. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs. 2009;20(6): 477-482.
23. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29(19):2635-2644.
24. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645-2652.
25. Powe DG, Voss MJ, Zänker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-638.
26. Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10): 797-809.
27. Campbell JP, Karolak MR, Ma Y, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012;10(7):e1001363.
28. Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila). 2012;5(8): 1007-1014.
29. Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N, Petrovic T, Juranic Z. Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res. 2005;24(3):387-395.
30. Shan T, Ma Q, Zhang D, et al. β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol. 2011;665(1-3):1-7.
31. Maturo S, Tse SM, Kinane TB, Hartnick CJ. Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2011; 120(1):17-20.
32. Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep. 2010;24(6):1669-1676.
33. Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, Baran Y. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. J Cancer Res Clin Oncol. 2012. Epub Oct 19.
34. Raffegerst SH, Hoelzlwimmer G, Kunder S, Mysliwietz J, Quintanilla-Martinez L, Schendel DJ. Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice. PLoS One. 2009;4(12):e8539.
35. García-Plata D, Mozos E, Carrasco L, Solana R. HLA molecule expression in cutaneous squamous cell carcinomas: an immunopathological study and clinical-immunohistopathological correlations. Histol Histopathol. 1993;8(2):219-226.
36. Makni H, Daoud J, Ben Salah H, et al. HLA association with nasopharyngeal carcinoma in southern Tunisia. Mol Biol Rep. 2010;37(5): 2533-2539.
37. Panza N, Del Vecchio L, Maio M, et al. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens. 1982;20(2): 155-158.
38. Lindhorst E, Schumm-Draeger PM, Bojunga J, Usadel KH, Herrmann G. Differences in tumor cell proliferation, HLA DR expression and lymphocytic infiltration in various types of thyroid carcinoma. Exp Clin Endocrinol Diabetes. 2002;110(1):27-31.
39. Donaldson PT, Ho S, Williams R, Johnson PJ. HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver. 2001;21(2): 143-148.
40. Lee HW, Hahm KB, Lee JS, Ju YS, Lee KM, Lee KW. Association of the human leukocyte antigen class II alleles with chronic atrophic gastritis and gastric carcinoma in Koreans. J Dig Dis. 2009;10(4): 265-271.
41. Ando T, Ishikawa T, Kato H, et al. Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter pylori infection. Int J Cancer. 2009;125(11):2595-2602.
42. Michel S, Linnebacher M, Alcaniz J, et al. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer. 2010; 127(4):889-898.
43. Hernández-Hernández DM, Cerda-Flores RM, Juárez-Cedillo T, et al. Human leukocyte antigens I and II haplotypes associated with human papillomavirus 16-positive invasive cervical cancer in Mexican women. Int J Gynecol Cancer. 2009;19(6):1099-1106.
44. Ozdemir E, Kakehi Y, Mishina M, et al. High-resolution HLA-DRB1 and DQB1 genotyping in Japanese patients with testicular germ cell carcinoma. Br J Cancer. 1997;76(10):1348-1352.
45. Choi HB, Roh SY, Choi EJ, et al. Association of HLA alleles with non-Hodgkin's lymphoma in Korean population. Int J Hematol. 2008;87(2): 203-209.
46. Ozdilli K, Oguz FS, Anak S, Kekik C, Carin M, Gedikoglu G. The frequency of HLA class I and II alleles in Turkish childhood acute leukaemia patients. J Int Med Res. 2010;38(5):1835-1844.
47. Naugler C, Liwski R. HLA risk markers for chronic myelogenous leukemia in Eastern Canada. Leuk Lymphoma. 2009;50(2):254-259.
48. Hojjat-Farsangi M, Jeddi-Tehrani M, Amirzargar AA, et al. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. Hum Immunol. 2008;69(10):666-674.
49. Limas CJ, Goldenberg IF, Limas C. Influence of anti-beta-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am Heart J. 1990;119(6):1322-1328.
50. Li Q, Milo R, Panitch H, Bever CT Jr. Effect of propranolol and IFN-beta on the induction of MHC class II expression and cytokine production by IFN-gamma IN THP-1 human monocytic cells. Immunopharmacol Immunotoxicol. 1998;20(1):39-61.
51. Shaw SM, Coppinger T, Waywell C, et al. The effect of beta-blockers on the adaptive immune system in chronic heart failure. Cardiovasc Ther. 2009;27(3):181-186.
52. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994;23(2): 258-268.
53. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16(7):293-299.
54. Lotfy M, El-Kenawy A.-M, Abdel-Aziz MM, El-Kady I, Talaat A. Elevated renin levels in patients with liver cirrhosis and hepatocellular carcinoma. Asian Pac J Cancer Prev. 2010;11(5):1263-1266.
55. Beyazit Y, Purnak T, Suvak B, et al. Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. Clin Res Hepatol Gastroenterol. 2011;35(10):644-649.
56. Aksu S, Beyazit Y, Haznedaroglu IC, et al. Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leuk Lymphoma. 2006;47(5):891-896.
57. Koca E, Haznedaroglu IC, Uner A, Sayinalp N, Saglam AE, et al. Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease. J Natl Med Assoc. 2007;99(11):1243-1244, 1246-1247.
58. Huang W, Yu LF, Zhong J, et al. Angiotensin II type 1 receptor expression in human gastric cancer and induces MMP2 and MMP9 expression in MKN-28 cells. Dig Dis Sci. 2008;53(1):163-168.
59. Louis SN, Wang L, Chow L, et al. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate. Cancer Detect Prev. 2007;31(5):391-395.
60. Feng Y, Ni L, Wan H, et al. Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 2011;26(5):1157-1164.
61. Ino K, Shibata K, Kajiyama H, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 2006;94(4):552-560.
62. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94(12):4735-4741.
63. Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, et al. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst. 2009;10(1):51-58.
64. González-Zuloeta Ladd AM, Arias Vásquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2143-2146.
65. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112(4):748-757.
66. Wang X, Wang S, Lin YW, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol. 2012;29(3):1964-1971.
67. Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010;23(4):941-948.
68. Zhou L, Zhang R, Yao W, Wang J, Qian A, et al. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J Exp Med. 2009;217(2): 123-131.
69. Zhou L, Zhang R, Zhang L, Yao W, Li J, Yuan Y. Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett. 2011;307(1):18-25.
70. Kinoshita J, Fushida S, Harada S, et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol. 2009;34(6):1573-1582.
71. Du N, Feng J, Hu LJ, et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep. 2012;27(6):1893-1903.
72. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135(10):1429-1435.
73. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010;103(11):1644-1648.
74. Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47(13): 1955-1961.
75. Ming M, Wu J, Lachance S, Delalandre A, Carrière S, Chan JS. Beta-adrenergic receptors and angiotensinogen gene expression in mouse hepatoma cells in vitro. Hypertension. 1995;25(1):105-109.
76. Nakamaru M, Jackson EK, Inagami T. Beta-adrenoceptor-mediated release of angiotensin II from mesenteric arteries. Am J Physiol. 1986; 250(1 Pt 2):H144-H148.
77. Richards EM, Hermann K, Sumners C, Raizada MK, Phillips MI. Release of immunoreactive angiotensin II from neuronal cultures: adrenergic influences. Am J Physiol. 1989;257(3 Pt 1):C588-C595.
78. Tang SS, Stevenson L, Dzau VJ. Endothelial renin-angiotensin pathway. Adrenergic regulation of angiotensin secretion. Circ Res. 1990;66(1): 103-108.
79. Taddei S, Favilla S, Duranti P, Simonini N, Salvetti A. Vascular renin-angiotensin system and neurotransmission in hypertensive persons. Hypertension. 1991;18(3):266-277.
80. Vilas-Boas WW, Ribeiro-Oliveira A Jr, Ribeiro Rda C, et al. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol. 2008;14(44): 6824-6830.
81. Saijonmaa O, Nyman T, Fyhrquist F. Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. J Cardiovasc Pharmacol. 2004;43(5):616-621.
82. Cohen Solal A, Jondeau G, Beauvais F, Berdeaux A. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail. 2004;6(4):463-466.
83. Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg. 2011;64(6):759-765.
84. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
85. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3): e423-e431.
86. Shukla S, MacLennan GT, Fu P, et al. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia. 2004;6(4): 390-400.
87. Furukawa K, Uwagawa T, Haruki K, et al. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Surg Today. 2012. Epub Aug 15.
88. Ozbek E, Aliskan T, Otunctemur A, et al. Comparison of tumor grade and stage with nuclear factor kappa b and p38 mitogene activated protein kinase expressions in renal cell cancer. Arch Ital Urol Androl. 2012;84(2):53-60.
89. Spirina LV, Yunusova NV, Kondakova IV, et al. Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer. Mol Biol Rep. 2012;39(9):8655-8662.
90. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer. 2011;11:136.
91. Yu Y, Liu H, Jin M, et al. The joint association of REST and NFKB1 polymorphisms on the risk of colorectal cancer. Ann Hum Genet. 2012;76(4):269-276.
92. Lin CW, Hsieh YS, Hsin CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS One. 2012;7(4):e35078.
93. Song S, Chen D, Lu J, et al. NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS One. 2011;6(6):e21726.
94. Wang X, Lu P, Xu L, et al. Updated meta-analysis of NFkappaB1-94 ins/Delattg promoter polymorphism and cancer risk based on 19 case-control studies. Asian Pac J Cancer Prev. 2011;12(10):2479-2484.
95. Fan Y, Yu W, Ye P, Wang H, Wang Z, et al. NFKB1 insertion/deletion promoter polymorphism increases the risk of advanced ovarian cancer in a Chinese population. DNA Cell Biol. 2011;30(4):241-245.
96. Zhou B, Qie M, Wang Y, et al. Relationship between NFKB1-94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Ann Oncol. 2010;21(3):506-511.
97. Wang S, Zhang M, Zeng Z, et al. IκBα polymorphisms were associated with increased risk of gastric cancer in a southern Chinese population: a case-control study. Life Sci. 2011;88(17/18):792-797.
98. Li Y, Shi J, Yang BF, et al. Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. Br J Pharmacol. 2012; 165(6):1748-1756.
99. Yang SP, Ho LJ, Lin YL, et al. Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc Res. 2003;59(3): 776-787.
100. Zhang D, Ma QY, Hu HT, Zhang M. β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 2010;10(1):19-29.
101. Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer. 2003;38(4):339-348.
102. Tong WM, Yang YG, Cao WH, et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene. 2007;26(26):3857-3867.
103. Tong WM, Cortes U, Hande MP, et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 2002;62(23):6990-6996.
104. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res. 1990;50(1): 38-43.
105. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol. 1991;37(4):223-227.
106. Nosho K, Yamamoto H, Mikami M, et al. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer. 2006;42(14):2374-2381.
107. Quiles-Perez R, Muñoz-Gámez JA, Ruiz-Extremera A, et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology. 2010;51(1):255-266.
108. Rojo F, García-Parra J, Zazo S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012;23(5):1156-1164.
109. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Gore L, Liu AK, Foreman NK. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer. 2009;53(7):1227-1230.
110. Barnett JC, Bean SM, Nakayama JM, Kondoh E, Murphy SK, Berchuck A. High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer. Obstet Gynecol. 2010;115(1):49-54.
111. Gonçalves A, Finetti P, Sabatier R, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;127(1):273-281.
112. Zhang Q, Li Y, Li X, et al. PARP-1 Val762Ala polymorphism, CagA+ H. pylori infection and risk for gastric cancer in Han Chinese population. Mol Biol Rep. 2009;36(6):1461-1467.
113. Lockett KL, Hall MC, Xu J, et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 2004;64(17):6344-6348.
114. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res. 2004;64(12):4378-4384.
115. Zhang J, Jin X, Fang S, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis. 2005;26(10):1748-1753.
116. Jin XM, Kim HN, Lee IK, Park KS, Kim HJ, et al. PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males. BMC Med Genet. 2010;11:38.
117. Wang XG, Wang ZQ, Tong WM, Shen Y. PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun. 2007;354(1):122-126.
118. Yu H, Ma H, Yin M, Wei Q. Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. Genet Epidemiol. 2011;36(1):56-65.
119. Oláh G, Finnerty CC, Sbrana E, et al. Increased poly(ADP-ribosyl)ation in skeletal muscle tissue of pediatric patients with severe burn injury: prevention by propranolol treatment. Shock. 2011;36(1):18-23.
120. Mikami M, Goubaeva F, Song JH, Lee HT, Yang J. Beta-Adrenoceptor blockers protect against staurosporine-induced apoptosis in SH-SY5Y neuroblastoma cells. Eur J Pharmacol. 2008;589(1-3): 14-21.
121. Usta E, Mustafi M, Straub A, Ziemer G. The nonselective beta-blocker carvedilol suppresses apoptosis in human cardiac tissue: a pilot study. Heart Surg Forum. 2010;13(4):E218-E222.
122. Habon T, Szabados E, Kesmarky G, et al. The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals. Cardiovasc Res. 2001;52(1):153-160.
123. Strosznajder RP, Jesko H, Dziewulska J. Effect of carvedilol on neuronal survival and poly(ADP-ribose) polymerase activity in hippocampus after transient forebrain ischemia. Acta Neurobiol Exp (Wars). 2005;65(2):137-143.
124. Osborne NN, Wood JP. Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs. Invest Ophthalmol Vis Sci. 2004;45(10):3787-3795.
125. Partyka R, Gonciarz M, Jałowiecki P, Kokocińska D, Byrczek T. VEGF and metalloproteinase 2 (MMP 2) expression in gastric cancer tissue. Med Sci Monit. 2012;18(4):BR130-BR134.
126. Zaravinos A, Volanis D, Lambrou GI, Delakas D, Spandidos DA. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep. 2012;28(4):1159-1166.
127. Zhou ZH, Cui XN, Xing HG, Yan RH, Yao DK, Wang LX. Changes and Prognostic Value of Serum Vascular Endothelial Growth Factor in Patients with Differentiated Thyroid Cancer. Med Princ Pract. Epub August 8, 2012.
128. Gray RT, O'Donnell ME, McGuigan JA, Spence GM. Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study. Br J Biomed Sci. 2012;69(2):71-75.
129. Villarejo-Campos P, Padilla-Valverde D, Martin RM, et al. Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol. Epub July 24, 2012.
130. Lammli J, Fan M, Rosenthal HG, et al. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012;36(11):2307-2313.
131. Yen CJ, Lin YJ, Yen CS, et al. Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012;7(7): e41931.
132. Arias-Pulido H, Chaher N, Gong Y, Qualls C, Vargas J, Royce M. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer. BMC Cancer. 2012;12: 298.
133. Bandiera E, Franceschini R, Specchia C, et al. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol. 2012;2012: 245756.
134. Li Y, Liang J, Liu X, et al. Correlation of polymorphisms of the vascular endothelial growth factor gene and the risk of lung cancer in an ethnic Han group of North China. Exp Ther Med. 2012;3(4): 673-676.
135. Supic G, Jovic N, Zeljic K, Kozomara R, Magic Z. Association of VEGF-A genetic polymorphisms with cancer risk and survival in advanced-stage oral squamous cell carcinoma patients. Oral Oncol. 2012;48(11):1171-1177.
136. Zhao Z, Ba C, Wang W, Wang X, Xue R, Wu X. Vascular endothelial growth factor (VEGF) gene polymorphisms and colorectal cancer: a meta-analysis of epidemiologic studies. Genet Test Mol Biomarkers. 2012;16(12):1390-1394.
137. Hu K, Zhang Y, Wang R, Li G, Li G, Zhang D. Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies. Twin Res Hum Genet. 2012;15(4): 496-502.
138. Peng L, Zhan P, Zhou Y, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39(10):9473-9484.
139. Zang J, Li C, Zhao LN, et al. Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis. Head Neck. Epub September 18, 2012.
140. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514-4521.
141. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66(21):10357-10364.
142. Hajighasemi F, Hajighasemi S. Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro. Iran Biomed J. 2009;13(4):223-228.
143. Wong HP, Ho JW, Koo MW, et al. Effects of adrenaline in human colon adenocarcinoma HT-29 cells. Life Sci. 2011;88(25/26):1108-1112.
144. Kamata T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci. 2009;100(8):1382-1388.
145. Block K, Gorin Y, New DD, et al. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol. 2010;176(5):2447-2455.
146. Yamaura M, Mitsushita J, Furuta S, et al. NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression. Cancer Res. 2009;69(6):2647-2654.
147. Maraldi T, Prata C, Vieceli Dalla Sega F, et al. NAD(P)H oxidase isoform Nox2 plays a prosurvival role in human leukaemia cells. Free Radic Res. 2009;43(11):1111-1121.
148. Hong J, Resnick M, Behar J, et al. Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):G697-G706.
149. Lu CL, Qiu JL, Huang PZ, et al. NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumour Biol. 2011;32(6):1173-1182.
150. Kim J, Koyanagi T, Mochly-Rosen D. PKCδ activation mediates angiogenesis via NADPH oxidase activity in PC-3 prostate cancer cells. Prostate. 2011;71(9):946-954.
151. Wang R, Dashwood WM, Nian H, et al. NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Int J Cancer. 2011;128(11):2581-2590.
152. Hsieh CH, Shyu WC, Chiang CY, Kuo JW, Shen WC, Liu RS. NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS One. 2011;6(9):e23945.
153. Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012;119(3):810-816.
154. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res. 2000;6(10): 4091-4095.
155. Fern L, Pallis M, Ian Carter G, Seedhouse C, Russell N, Byrne J. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol. 2004;126(1):63-71.
156. Hamajima N, Matsuo K, Iwata H, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7(2):103-108.
157. Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet. 2005;162(1):10-20.
158. Lan Q, Zheng T, Shen M, et al. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet. 2007;121(2):161-168.
159. Hoffmann M, Schirmer MA, Tzvetkov MV, et al; German Study Group for High-Grade Non-Hodgkin Lymphoma. A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma. Cancer Res. 2010;70(6):2328-2338.
160. Gra OA, Glotov AS, Kozhekbaeva ZH, Makarova OV, Nasedkina TV. Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. Mol Biol (Mosk). 2008;42(2):214-225. Russian.
161. Seibold P, Hein R, Schmezer P, et al. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer. 2011;129(6):1467-1476.
162. Malik MA, Sharma KL, Zargar SA, Mittal B. Association of matrix metalloproteinase-7 (-181A.G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J Gastroenterol. 2011;17(5):301-306.
163. Sorrentino SA, Doerries C, Manes C, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol. 2011;57(5):601-611.
164. Manrique C, Lastra G, Habibi J, et al. Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism. 2011;60(12):1757-1766.
165. Whaley-Connell A, Habibi J, Johnson M, et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol. 2009;30(4):354-360.
166. Zhou X, Ma L, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension. 2010;55(4):880-888.
167. Arozal W, Watanabe K, Veeraveedu PT, et al. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology. 2010;274(1/3):18-26.
168. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol. 2003;23(4):615-621.
169. Kobayashi N, Mita S, Yoshida K, et al. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 Via NF-kappaB induced by oxidative stress. Hypertension. 2003;42(5): 1004-1013.
170. Garamszegi N, Garamszegi SP, Scully SP. Matrix metalloproteinase-1 contribution to sarcoma cell invasion. J Cell Mol Med. 2012;16(6): 1331-1341.
171. Dong W, Li H, Zhang Y, et al. Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim Biophys Sin (Shanghai). 2011;43(11):840-848.
172. Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta. 2012;413(13/14):1121-1126.
173. Qiu J, Shao S, Yang G, Shen Z, Zhang Y. Association of Toll like receptor 9 expression with lymph node metastasis in human breast cancer. Neoplasma. 2011;58(3):251-255.
174. Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011;31(10):3423-3428.
175. Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011;1411:108-115.
176. Xia Z, Liu W, Li S, et al. Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma. Neurochem Res. 2011;36(12):2346-2351.
177. Feng S, Cen J, Huang Y, et al. Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS One. 2011;6(8): e20599.
178. Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer. 1998;78(11):1495-1502.
179. Altaş M, Bayrak OF, Ayan E, et al. The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma. Acta Neurochir (Wien). 2010;152(9): 1611-1617.
180. Tee YT, Liu YF, Chang JT, et al. Single-nucleotide polymorphisms and haplotypes of membrane type 1-matrix metalloproteinase in susceptibility and clinical significance of squamous cell neoplasia of uterine cervix in Taiwan women. Reprod Sci. 2012;19(9): 932-938.
181. Srivastava P, Lone TA, Kapoor R, Mittal RD. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res. 2012;43(2):117-124.
182. Zhao X, Wang X, Wu W, et al. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy. Cancer. 2012;118(14):3587-3598.
183. Dziki L, Przybyłowska K, Majsterek I, Trzciński R, Mik M, Sygut A. A/G polymorphism of the MMP-7 gene promoter region in colorectal cancer. Pol Przegl Chir. 2011;83(11):622-626.
184. Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 2011;16(7):577-586.
185. Wieczorek E, Reszka E, Gromadzinska J, Wasowicz W. Genetic polymorphism of matrix metalloproteinases in breast cancer. Neoplasma. 2012;59(3):237-247.
186. Zhang LY, Ren KW. Meta-analysis of MMP2 -1306T allele as a protective factor in digestive cancer. Arch Med Res. 2011;42(3): 239-243.
187. Zhang LF, Mi YY, Cao Q, et al. Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Mol Biol Rep. 2012;39(4):3435-3441.
188. Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012;7(2):e31251.
189. Liu D, Duan W, Guo H, Xu X, Bai Y. Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. Int J Colorectal Dis. 2011;26(9):1099-1105.
190. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res. 2009;60(5):438-445.
191. Lirussi F, O'Brien M, Wendremaire M, et al. SAR150640, a selective beta3-adrenoceptor agonist, prevents human myometrial remodelling and activation of matrix metalloproteinase in an in vitro model of chorioamnionitis. Br J Pharmacol. 2010;159(6):1354-1366.
192. Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep. 2009; 22(4):825-830.
193. Hipskind RA, Bilbe G. MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci. 1998;3:d804-d816.
194. Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT. Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest. 2012. 2012;42(12):1295-1301.
195. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun. 1998;250(1):43-47.
196. Hori M, Inagawa S, Shimazaki J, Itabashi M, Hori M. Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer. Pathol Res Pract. 2000;196(12):817-826.
197. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene. 2012. Epub September 3.
198. Al-Azayzih A, Gao F, Goc A, Somanath PR. TGFβ1 induces apoptosis in invasive prostate cancer and bladder cancer cells via Akt-independent, p38 MAPK and JNK/SAPK-mediated activation of caspases. Biochem Biophys Res Commun. 2012;427(1):165-170.
199. Slattery ML, Lundgreen A, Wolff RK. MAPKinase genes and colon and rectal cancer. Carcinogenesis. 2012;33(12):2398-2408.
200. Gröschl B, Bettstetter M, Giedl C, et al. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer. Epub September 11, 2012.
201. Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology. 2012;59(115):889-893.
202. Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg. 2012;256(1):146-156.
203. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer. 2001; 85(7):1023-1031.
204. Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer. 2001;93(5):681-686.
205. Gatalica Z, Lilleberg SL, Koul MS, et al. COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors. Hum Pathol. 2008;39(10):1495-1504.
206. Okawa T, Yoshinaga K, Uetake H, et al. Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas. Dis Colon Rectum. 2004;47(11):1915-1921.
207. Leung WK, To KF, Ng YP, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84(3):335-339.
208. Sales KJ, Katz AA, Davis M, et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab. 2001;86(5):2243-2249.
209. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, et al. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -. C COX-2 polymorphism. Clin Cancer Res. 2005;11(11):4090-4096.
210. Markosyan N, Chen EP, Ndong VN, et al. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis. 2011;32(10):1441-1449.
211. Santander S, Cebrián C, Esquivias P, et al. Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice. Int J Oncol. 2012;40(2): 527-534.
212. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001;93(4):497-506.
213. Kang S, Kim YB, Kim MH, et al. Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. 2005; 217(1):11-16.
214. Sakoda LC, Gao YT, Chen BE, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis. 2006;27(6):1251-1256.
215. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer. 2006;6:70.
216. Lira MG, Mazzola S, Tessari G, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol. 2007;157(1):49-57.
217. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res. 2009;663(1-2): 52-59.
218. Ben Nasr H, Chahed K, Bouaouina N, Chouchane L. PTGS2 (COX-2) -765 G> C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep. 2009;36(1):193-200.
219. Zhao D, Xu D, Zhang X, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009;136(5):1659-1668.
220. Lurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010;21(10):1731-1741.
221. Abraham JE, Harrington P, Driver KE, et al. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res. 2009;15(6): 2181-2191.
222. Li Y, He W, Liu T, Zhang Q. A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma. Mol Diagn Ther. 2010;14(6):351-355.
223. Zheng J, Chen S, Jiang L, You Y, Wu D, Zhou Y. Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol. 2011;87(6): 486-493.
224. Amirian ES, Ittmann MM, Scheurer ME. Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. Prostate. 2011;71(13):1382-1389.
225. Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck. 2009;31(7):938-943.
226. Gong Z, Bostick RM, Xie D, et al. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis. 2009;24(6):647-654.
227. Akkiz H, Bayram S, Bekar A, Akgöllü E, Ülger Y. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem. 2011;347(1-2):201-208.
228. Dong J, Dai J, Zhang M, Hu Z, Shen H. Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol. 2010;25(6): 1042-1050.
229. Zhu W, Wei BB, Shan X, Liu P. -765G.C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep. 2010;37(1):277-288.
230. Shrubsole MJ, Cai Q, Wen W, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res (Phila). 2012; 5(2):336-342.
231. Hogendorf P, Durczyński A, Kumor A, Strzelczyk J. Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor-a single institution series. J Invest Surg. 2012;25(1):8-13.
232. Rasmuson A, Kock A, Fuskevåg OM, et al. Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One. 2012;7(1):e29331.
233. Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun. 2004;314(4):1093-1099.
234. Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol. 2010;184(5):2449-2457.
235. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol. 2008;15(7):2042-2052.
236. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16(11):1295-1322.
237. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171.
238. Zhang Q, Ma Y, Cheng YF, Li WJ, Zhang Z, Chen SY. Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer Lett. 2011;313(2):201-210.
239. Wang HC, Choudhary S. Reactive oxygen species-mediated therapeutic control of bladder cancer. Nat Rev Urol. 2011;8(11):608-616.
240. Rogalska A, Gajek A, Szwed M, Jóźwiak Z, Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol in Vitro. 2011;25(8):1712-1720.
241. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2): 155-162.
242. Hong CC, Ambrosone CB, Ahn J, et al. Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1784-1794.
243. Woodson K, Tangrea JA, Lehman TA, et al. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control. 2003;14(6): 513-518.
244. Wang S, Wang F, Shi X, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk-A meta-analysis. Eur J Cancer. 2009;45(16):2874-2881.
245. Mao C, Qiu LX, Zhan P, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol. 2010;136(7):975-979.
246. Ma X, Chen C, Xiong H, et al. No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: a meta-analysis based on 9,710 cases and 11,041 controls. Breast Cancer Res Treat. 2010;122(2):509-514.
247. Larson BE, Stockwell DW, Boas S, Andrews T, Wellman GC, et al. Cardiac reactive oxygen species after traumatic brain injury. J Surg Res. 2012;173(2):e73-81.
248. Ma L, Gul R, Habibi J, et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol. 2012; 302(11):H2341-H2351.
249. Le Pennec S, Mirebeau-Prunier D, Boutet-Bouzamondo N, et al. Nitric oxide and calcium participate in the fine regulation of mitochondrial biogenesis in follicular thyroid carcinoma cells. J Biol Chem. 2011; 286(20):18229-18239.
250. Bentz BG, Chandra R, Haines GK 3rd, Robinson AM, Shah P, Radosevich JA. Nitric oxide and apoptosis during human head and neck squamous cell carcinoma development. Am J Otolaryngol. 2002;23(1):4-11.
251. Siripin D, Fucharoen S, Tanyong DI. Nitric oxide and caspase 3mediated cytokine induced apoptosis in acute leukemia. Asian Pac J Allergy Immunol. 2011;29(1):102-111.
252. Saleem W, Suzuki Y, Mobaraki A, Yoshida Y, Noda S, et al. Reduction of nitric oxide level enhances the radiosensitivity of hypoxic non-small cell lung cancer. Cancer Sci. 2011;102(12):2150-2156.
253. Guler E, Baspinar O, Cekmen M, Kilinc M, Balat A. Nitric oxide: a new biomarker of Doxorubicin toxicity in children? Pediatr Hematol Oncol. 2011;28(5):395-402.
254. Chin MP, Deen WM. Prediction of nitric oxide concentrations in melanomas. Nitric Oxide. 2010;23(4):319-326.
255. Ellie E, Loiseau H, Lafond F, Arsaut J, Demotes-Mainard J. Differential expression of inducible nitric oxide synthase mRNA in human brain tumours. Neuroreport. 1995;7(1):294-296.
256. Zhang W, He XJ, Ma YY, et al. Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Hum Pathol. 2011;42(9): 1275-1282.
257. Glynn SA, Boersma BJ, Dorsey TH, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010;120(11):3843-3854.
258. Cardnell RJ, Mikkelsen RB. Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One. 2011;6(5):e20147.
259. Ryk C, Steineck G, Wiklund NP, Nyberg T, de Verdier PJ. The (CCTTT)n microsatellite polymorphism in the nitric oxide synthase 2 gene may influence bladder cancer pathogenesis. J Urol. 2010;184(5): 2150-2157.
260. Shen CH, Wang YH, Wang WC, et al. Inducible nitric oxide synthase promoter polymorphism, cigarette smoking, and urothelial carcinoma risk. Urology. 2007;69(5):1001-1006.
261. Kaise M, Miwa J, Suzuki N, et al. Inducible nitric oxide synthase gene promoter polymorphism is associated with increased gastric mRNA expression of inducible nitric oxide synthase and increased risk of gastric carcinoma. Eur J Gastroenterol Hepatol. 2007;19(2): 139-145.
262. Arikan S, Cacina C, Guler E, Çulcu S, Tuna G, Yaylim-Eraltan I. The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish population. Mol Biol Rep. 2012;39(3): 3245-3249.
263. Han X, Zheng T, Lan Q, et al. Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1429-1438.
264. Hao Y, Montiel R, Huang Y. Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;124(3):809-813.
265. Dai Y, Hou F, Buckmiller L, et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Arch Otolaryngol Head Neck Surg. 2012;138(2):177-182.